These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo distribution of arsonoliposomes: effect of vesicle lipid composition. Zagana P; Haikou M; Klepetsanis P; Giannopoulou E; Ioannou PV; Antimisiaris SG Int J Pharm; 2008 Jan; 347(1-2):86-92. PubMed ID: 17689900 [TBL] [Abstract][Full Text] [Related]
3. Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study. Zagana P; Haikou M; Giannopoulou E; Ioannou PV; Antimisiaris SG Mol Nutr Food Res; 2009 May; 53(5):592-9. PubMed ID: 18727012 [TBL] [Abstract][Full Text] [Related]
4. Incorporation of PEG-lipids in arsonoliposomes results in formation of highly stable arsenic-containing vesicles. Piperoudi S; Fatouros D; Ioannou PV; Frederik P; Antimisiaris SG Chem Phys Lipids; 2006 Feb; 139(2):96-106. PubMed ID: 16405880 [TBL] [Abstract][Full Text] [Related]
5. In-vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in-vivo distribution in BALB/c mice. Antimisiaris SG; Ioannou PV; Loiseau PM J Pharm Pharmacol; 2003 May; 55(5):647-52. PubMed ID: 12831507 [TBL] [Abstract][Full Text] [Related]
6. The effect of pH on the electrophoretic behaviour of a new class of liposomes: arsonoliposomes. Fatouros DG; Klepetsanis P; Ioannou PV; Antimisiaris SG Int J Pharm; 2005 Jan; 288(1):151-6. PubMed ID: 15607267 [TBL] [Abstract][Full Text] [Related]
7. Arsonoliposomes: effect of lipid composition on their stability and morphology. Piperoudi S; Ioannou PV; Frederik P; Antimisiaris SG J Liposome Res; 2005; 15(3-4):187-97. PubMed ID: 16393910 [TBL] [Abstract][Full Text] [Related]
8. Arsonoliposome interaction with thiols: effect of pegylation and arsonolipid content of arsonoliposomes on their integrity during incubation in glutathione. Haikou MN; Zagana P; Ioannou PV; Antimisiaris SG J Nanosci Nanotechnol; 2006; 6(9-10):2974-8. PubMed ID: 17048506 [TBL] [Abstract][Full Text] [Related]
12. Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Managit C; Kawakami S; Nishikawa M; Yamashita F; Hashida M Int J Pharm; 2003 Nov; 266(1-2):77-84. PubMed ID: 14559396 [TBL] [Abstract][Full Text] [Related]
13. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Hadinoto K; Sundaresan A; Cheow WS Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180 [TBL] [Abstract][Full Text] [Related]
14. Arsonoliposomes: effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture. Gortzi O; Antimisiaris SG; Klepetsanis P; Papadimitriou E; Ioannou PV Eur J Pharm Sci; 2003 Feb; 18(2):175-83. PubMed ID: 12594011 [TBL] [Abstract][Full Text] [Related]
15. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Papagiannaros A; Bories C; Demetzos C; Loiseau PM Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367 [TBL] [Abstract][Full Text] [Related]
16. A correlation between lipid domain shape and binary phospholipid mixture composition in free standing bilayers: A two-photon fluorescence microscopy study. Bagatolli LA; Gratton E Biophys J; 2000 Jul; 79(1):434-47. PubMed ID: 10866969 [TBL] [Abstract][Full Text] [Related]
17. Haemolytic activity of liposomes: effect of vesicle size, lipid concentration and polyethylene glycol-lipid or arsonolipid incorporation. Mourtas S; Michanetzis GP; Missirlis YF; Antimisiaris SG J Biomed Nanotechnol; 2009 Aug; 5(4):409-15. PubMed ID: 20055087 [TBL] [Abstract][Full Text] [Related]
18. In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. Antimisiaris SG; Klepetsanis P; Zachariou V; Giannopoulou E; Ioannou PV Int J Pharm; 2005 Jan; 289(1-2):151-8. PubMed ID: 15652207 [TBL] [Abstract][Full Text] [Related]